



## Lesotho COVID-19 Emergency Preparedness and Response Project (P173939)

EASTERN AND SOUTHERN AFRICA | Lesotho | Health, Nutrition & Population Global Practice | IBRD/IDA | Investment Project Financing | FY 2020 | Seq No: 8 | ARCHIVED on 10-Nov-2023 | ISR58137 |

Implementing Agencies: Kingdom of Lesotho, Ministry of Health

**Key Dates****Key Project Dates**

Bank Approval Date: 09-May-2020

Effectiveness Date: 27-May-2020

Planned Mid Term Review Date: 31-May-2022

Actual Mid-Term Review Date: 03-May-2022

Original Closing Date: 30-Jun-2022

Revised Closing Date: 30-Jun-2024

**Project Development Objectives**

Project Development Objective (from Project Appraisal Document)

To prevent, detect and respond to the threat posed by COVID-19 to the Kingdom of Lesotho.

Has the Project Development Objective been changed since Board Approval of the Project Objective?

No

**Components Table**

Name

Component 1: Emergency COVID-19 Response:(Cost \$29675000.00 M)

Component 2: Project Implementation and Monitoring & Evaluation:(Cost \$3325000.00 M)

**Overall Ratings**

Name	Previous Rating	Current Rating
Progress towards achievement of PDO	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Implementation Progress (IP)	<input type="checkbox"/> Satisfactory	<input type="checkbox"/> Satisfactory
Overall Risk Rating	<input type="checkbox"/> Substantial	<input type="checkbox"/> Substantial

**Implementation Status and Key Decisions**

The Lesotho COVID-19 Emergency Preparedness and Response Project aims to support the Government of Lesotho's (GOL) effort to prevent, detect and respond to the threat posed by SARS-COV-2. The project supported the procurement of critical equipment and medical supplies such as personal protective equipment for hospitals and health care workers, additional human resources and training, both for specialized and for community health workers, and the refurbishment of the Mafeteng COVID-19 treatment center, which provides critical medical care for COVID-19 patients in the district of Mafeteng and the country. In response to GOL's request for Additional Financing, the Bank approved on June 1, 2021, US\$22 million for the procurement and deployment of COVID-19 vaccines and an additional grant of US\$3.5 million from the Health Emergency Preparedness and Response Trust Fund (HEPR TF) to support the scale-up of the COVID-19 response, vaccine deployment and to further strengthen emergency preparedness. Therefore, the total project envelope is US\$33 million (US\$29.5 million from IDA and US\$3.5 million from HEPR TF). The project is aligned to the GOL's COVID-19 National Integrated Response Plan and complements support from other development partners in providing a comprehensive response to the GOL to manage the COVID-19 pandemic and implement the COVID 19 vaccination program.



## MPA Program Development Objective

The Program Development Objective is to prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness

## Multiphase Programmatic Approach (MPA) Status

### COVID-19 MPA - ISR Write-up as of October 16, 2023

Sustained efforts continue to be made to advance the implementation of the 87 MPA operations. After a great deal of activity (restructurings and disbursements) processed at the end of FY23 when several operations were restructured just before or on June 30, 2023, the past two months have seen a slower period of disbursements. The overall level of disbursements is being affected by three main reasons: (i) low disbursements in six countries, (ii) pausing of disbursements in three other countries – Afghanistan, Myanmar, and Sudan, and (iii) processing of refunds to the project accounts at this late stage of project implementation. In addition, (i) a large refund from the UN to the project account of the Myanmar operation was processed in late March due to the inability to implement the project, and (ii) Loans and Credits denominated in SDRs and Euros have been affected because of fluctuations between the SDRs and Euros against the US dollar.

As of October 16, 2023, 88 MPA-projects had been approved with a total commitment of US\$4.27 billion. One operation (Guatemala) was cancelled in mid-September 2021, at the request of the Government. **Total disbursements as of October 16, 2023, amount to US\$3.96 billion or 93% of overall commitments.** This amount does not include disbursements under MPA-V operations which are reported together with AF-V operations. Ten operations closed by the end of CY22 and nine operations closed on June 30, 2023. While there are sixteen (16) operations with closing dates by the end of CY23, there are plans for several projects to process extensions so this number will change.

**As with the Mid Term Review (MTR) issued on March 25, 2023, no individual COVID-19 MPA operation will need an ICR.** Only one ICR will be prepared upon completion of the SPRP COVID-19 MPA Program, which closes on December 31, 2025. The Global ICR will be based on final ISRs packages prepared by country operations' teams. A template for the final ISR was issued by OPCS on March 25, 2023. Several operations have/are preparing final ISR packages. **The overall conclusion of the MTR was that:** (i) the COVID-19 MPA Program embodied a rapid, innovative approach to new lending for human health response; (ii) the COVID-19 MPA has been successful, notwithstanding considerable uncertainty and multiple constraints in the early stages of the pandemic; (iii) the Bank's emergency response was remarkably swift in the most vulnerable countries facing human capital losses and development setbacks; and (iv) notwithstanding the challenges, the MPA is on track to achieve its PrDO, "prevent, detect and respond to the threat posed by COVID-19 and strengthen national systems for public health preparedness."

Seventy three (73) country projects or 86 percent of projects approved have reached 70-100+ percent disbursement (reasons for >100% disbursements relate to fluctuations between the Euro and the SDR against the US\$). Out of the 73 operations, 63 operations or 86 percent have disbursed 90+ percent of commitments. **Out of the 73 operations, 49 operations or 67 percent are fully disbursed** and ten (10) operations have disbursed 95-99 percent of commitments. There are four operations with disbursements of 50 percent or less. Out of these four operations, one operation has disbursed 35 percent (AFW), two operations in EAP have disbursed 46-48 percent and one operation in SAR has disbursed 49 percent. **The projects are benefitting about 3.7 billion people or 50% of the global population. When countries with AF-V operations are counted, the projects are benefitting about 4.1 billion of 51 percent of the global population.** This is because some countries that do not have a parent project have AF-V operations. All projects approved are disbursing. **Operations in ECA and MNA are fully disbursed.** In other regions, operations have reached: (i) SAR 94 percent, (ii) LAC 93 percent, (iii) EAP 86 percent, (iv) AFW 84, and (v) AFE 78 percent. Disbursements for EAP operations are being affected by low disbursements in three countries. AFE lower disbursements compared to other regions are a result of low disbursements under two operations, which have disbursed 54-66 percent respectively. In the case of AFW low overall disbursements are a result of



low disbursements under one operation. Retroactive Financing (RF) represents 19 percent of commitments. SAR has the highest percentage of RF at 37 percent, followed by ECA at 18 percent. IDA continues to represent 40 percent and IBRD 60 percent of disbursements.

Streamlined procedures, delegated approvals, coupled with flexible project design and intensified efforts across the Bank have contributed to the progress. Implementation is being guided by Bank teams working in parallel with other health related projects, including Additional Financing operations supporting vaccine procurement and deployment efforts.

#### **COVID-19 MPA AF-V - ISR Write-up – October 16, 2023**

As of October 16, 2023, the Bank has approved 117 operations (including MPA-V operations) to support vaccine procurement and rollout in 78 countries amounting to \$9.24 billion. The Senegal AF2 operation for \$15 million financed by a Grant from The Global Finance Facility was approved on June 30, 2023. Also, a Second AF (IDA Grant of \$1.50 million) was approved on August 31, 2023 for Sao Tome and Principe. One hundred and nineteen (119) operations had been approved amounting to \$10 billion, but the: (i) Costa Rica operation (\$120 million), and (ii) Peru operation (\$500 million) were cancelled at the request of both governments. Also, (i) the Gabon (\$12 million) reported in July as closed is still in the process of being closed, and (ii) the Afghanistan operation commitment of \$113 million was reduced to \$60 million. Partial cancellations have been processed in the past weeks under other operations, thereby the overall commitment has decreased in the past months. Of the 117 approved operations: (i) 67 are in Africa – 31 in AFE and 36 in AFW; (ii) 10 in East Asia and the Pacific; (iii) 11 in Europe and Central Asia; (iv) 11 in Latin America and the Caribbean; (v) 9 in Middle East and North Africa; and (vi) 9 in South Asia. The 117 operations approved, include 6 operations that involved restructuring of parent projects (Bhutan, Cameroon, North Macedonia, Philippines, and Pakistan) and in the case of Lebanon, restructuring of the Health Resilience Project.

Thirty-two (32) operations are being implemented in Fragile and Conflict-affected situations. IDA represents 45 percent and IBRD 55 percent of disbursements. **Total disbursements under these projects as of October 16, 2023, amount to US\$6.27 billion or 68 percent of overall commitments.** Disbursements under MPA-V operations are included in this total while disbursements under the six restructured projects are counted under parent projects. With less than planned demand for IDA/IBRD funds for vaccine procurement because, *inter alia*, over supply of vaccines from donations from various sources, several projects have been/are being restructured and more will need to be restructured to reallocate funds allocated for procurement of COVID-19 vaccines and deployment. **Guidance was issued under an Email from Juan Pablo Uribe of July 7, 2023, which provided direction for the use of undisbursed funds under COVID-19 operations.**

**Four (4) operations are fully disbursed (Argentina, Indonesia, Sri Lanka AF-V 1, and Ukraine AF-V 3).** Forty-seven (47) operations or 40 percent of operations approved have disbursed over 70 percent of their commitments. Out of the 47, eighteen (18) operations or 38 percent have disbursed 90+. Nine operations have disbursed 95-99 percent of commitments (Cabo Verde, Ecuador AF-V 1, Gambia AF-V 1 and 2, Iraq, South Sudan AF-V 2, Sierra Leone AF-V 1, Turkey, and Yemen). Ninety-five (95) operations or 81 percent of total operations approved are disbursing. ECA has the highest percentage of disbursements at 86 percent, followed by SAR and MNA at 77 percent, LAC at 76 percent, EAP at 74 percent, AFE at 58 percent and AFW at 57 percent. **As of August 1, 2023, the World Bank had purchased 635.4 million doses of the COVID-19 vaccine of which 506.8 million had been delivered to client countries and 500.7 million administered.**

Retroactive Financing (RF) represents 36 percent of overall commitments. High levels of RF have been authorized under different operations - Ukraine (100%), Panama and Turkey (90%), Argentina and Guyana (80%), and Belize, and Sri Lanka (70%). One hundred and fifteen (115) loan/financing agreements or 99 percent of projects approved have been signed and 114 or 99 percent have become effective.

As with the COVID-19 MPA operations, streamlined procedures, delegated approval, wide use of Bank Facilitated Procurement (BFP), coupled with flexible project design, and intensified efforts across the Bank have contributed to the rapid design, processing, and implementation of the AF-V operations.



**Risks**

**Systematic Operations Risk-rating Tool**

Risk Category	Rating at Approval	Previous Rating	Current Rating
Political and Governance	☐ Substantial	☐ Substantial	☐ Substantial
Macroeconomic	☐ Substantial	☐ Substantial	☐ Substantial
Sector Strategies and Policies	☐ Substantial	☐ Substantial	☐ Substantial
Technical Design of Project or Program	☐ Substantial	☐ Low	☐ Low
Institutional Capacity for Implementation and Sustainability	☐ Substantial	☐ Substantial	☐ Substantial
Fiduciary	☐ Substantial	☐ Moderate	☐ Moderate
Environment and Social	☐ Substantial	☐ Substantial	☐ Substantial
Stakeholders	☐ Moderate	☐ Moderate	☐ Moderate
Other	--	--	--
Overall	☐ Substantial	☐ Substantial	☐ Substantial

**Results**

**PDO Indicators by Objectives / Outcomes**

Emergency COVID-19 Response				
▶ Diagnosed cases treated per approved protocol (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	94.00	93.00	90.00
Date	27-Apr-2020	28-Feb-2023	02-Oct-2023	30-Jun-2024
▶ Total population vaccinated (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	47.00	48.00	50.00
Date	16-Apr-2021	28-Feb-2023	02-Oct-2023	30-Jun-2024
☐ Total female population vaccinated (Percentage, Custom Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	54.00	55.00	50.00



□ Total male population vaccinated (Percentage, Custom Supplement)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	41.00	42.00	50.00
▶ COVID-19 PCR tests processed within two days (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	15.00	100.00	100.00	70.00
Date	16-Apr-2021	28-Feb-2023	02-Oct-2023	30-Jun-2024

**Intermediate Results Indicators by Components**

Emergency COVID-19 Response				
▶ Grievances addressed on time (as specified in the Stakeholder Engagement Plan) (Percentage, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	98.00	84.00	100.00
Date	01-Dec-2020	28-Feb-2023	02-Oct-2023	30-Jun-2024
▶ Doses of eligible COVID-19 vaccines procured (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	892,800.00	741,600.00	741,600.00	800,000.00
Date	31-May-2022	28-Feb-2023	02-Oct-2023	30-Jun-2024
▶ Health staff trained in COVID-19 vaccination deployment per MOH-approved protocols (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	270.00	270.00	400.00
Date	19-Apr-2021	28-Feb-2023	02-Oct-2023	30-Jun-2024
□ Female health staff trained in COVID-19 vaccination deployment per MOH-approved protocols (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	211.00	211.00	300.00
Date	19-Apr-2021	28-Feb-2023	02-Oct-2023	30-Jun-2024



<input type="checkbox"/> Male health staff trained in COVID-19 vaccination deployment per MOH-approved protocols (Number, Custom Breakdown)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	59.00	59.00	100.00
Date	19-Apr-2021	28-Feb-2023	02-Oct-2023	30-Jun-2024
<b>▶ A patient feedback mechanism for COVID-19 vaccinations is in place and functional (Yes/No, Custom)</b>				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	Yes	Yes	Yes
Date	19-Apr-2021	28-Feb-2023	02-Oct-2023	30-Jun-2024
<b>▶ COVID-19 related information and education sessions targeting women (Number, Custom)</b>				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	604.00	773.00	500.00
Date	19-Apr-2021	28-Feb-2023	02-Oct-2023	30-Jun-2024
<b>▶ Serious AEFI after COVID-19 vaccination investigated (Percentage, Custom)</b>				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	100.00	92.00	95.00
Date	19-Apr-2021	28-Feb-2023	02-Oct-2023	30-Jun-2024
Comments:	Zero AEFIs reporting during the period under review.			
<b>▶ Intensive Care Units refurbished (Number, Custom)</b>				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	1.00	1.00	2.00	3.00
Date	19-Apr-2021	28-Feb-2023	02-Oct-2023	30-Jun-2024
<b>▶ National Reference Laboratory is expanded, equipped and functional (Yes/No, Custom)</b>				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	No	No	No	Yes
Date	19-Apr-2021	28-Feb-2023	02-Oct-2023	30-Jun-2024
Comments:	The works at the laboratory are 70% completed.			



▶ Health staff trained in COVID-19 case management per MOH-approved protocols (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	0.00	60.00	85.00
Date	19-Apr-2021	28-Feb-2023	02-Oct-2023	30-Jun-2024

▶ Oxygen plants established (Number, Custom)				
	Baseline	Actual (Previous)	Actual (Current)	End Target
Value	0.00	2.00	2.00	2.00
Date	19-Apr-2021	28-Feb-2023	02-Oct-2023	30-Jun-2024

**Performance-Based Conditions**

**Data on Financial Performance**


**Disbursements (by loan)**

Project	Loan/Credit/TF	Status	Currency	Original	Revised	Cancelled	Disbursed	Undisbursed	% Disbursed
P173939	IDA-66770	Effective	USD	7.50	7.50	0.00	7.21	0.29	96%
P173939	IDA-69300	Effective	USD	22.00	22.00	0.00	14.26	6.60	68%
P173939	TF-B5779	Effective	USD	3.50	3.50	0.00	3.05	0.45	87%

**Key Dates (by loan)**

Project	Loan/Credit/TF	Status	Approval Date	Signing Date	Effectiveness Date	Orig. Closing Date	Rev. Closing Date
P173939	IDA-66770	Effective	09-May-2020	12-May-2020	27-May-2020	30-Jun-2022	30-Jun-2024
P173939	IDA-69300	Effective	01-Jun-2021	11-Jun-2021	30-Jun-2021	30-Jun-2024	30-Jun-2024
P173939	TF-B5779	Effective	02-Jun-2021	11-Jun-2021	30-Jun-2021	30-Jun-2024	30-Jun-2024

**Cumulative Disbursements**



### Restructuring History

There has been no restructuring to date.

### Related Project(s)

P176307-AF Lesotho COVID-19 Emergency Preparedness and Response Project